7 research outputs found
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
A multiplex system to detect mutations at loci rs5985, rs1799983, rs5918, rs2243093, rs4673, rs4646994, rs1722009, rs3980933, rs71103505 associated with the development of cardiovascular diseases has been developed. These mutations belong to different types - SNP, STR, Ins/Del - therefore, minisequencing and fragment analysis technologies were used to determine them. Oligonucleotide analysis was performed to amplify all loci in a single reaction format. The minisequencing technology, in comparison with fragment analysis, required additional stages of sample preparation; therefore, oligonucleotides for loci with SNP were combined into a separate plex. For the two plexes created, the same composition of the amplification mixture and parameters of the PCR reaction program were optimized, and βbinβ panels were developed to interpret the results. The testing of the system confirmed the possibility of detecting mutations at nine loci with high sensitivity and reproducibility.Β Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π»ΠΎΠΊΡΡΠ°Ρ
rs5985, rs1799983, rs5918, rs2243093, rs4673, rs4646994, rs1722009, rs3980933, rs71103505, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΠ°Π½Π½ΡΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ ΠΎΡΠ½ΠΎΡΡΡΡΡ ΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ ΡΠΈΠΏΠ°ΠΌ - SNP, STR, Ins/Del - ΠΏΠΎΡΡΠΎΠΌΡ Π΄Π»Ρ ΠΈΡ
ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΌΠΈΠ½ΠΈΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄ΠΎΠ² Π΄Π»Ρ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π²ΡΠ΅Ρ
Π»ΠΎΠΊΡΡΠΎΠ² Π² ΡΠΎΡΠΌΠ°ΡΠ΅ ΠΎΠ΄Π½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. Π’Π΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΌΠΈΠ½ΠΈΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ ΠΏΠΎΡΡΠ΅Π±ΠΎΠ²Π°Π»Π° Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΡΠ°ΠΏΠΎΠ² ΠΏΡΠΎΠ±ΠΎΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ, Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ΅ΠΌ ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Ρ Π΄Π»Ρ Π»ΠΎΠΊΡΡΠΎΠ² Ρ SNP Π±ΡΠ»ΠΈ ΠΎΠ±ΡΠ΅Π΄ΠΈΠ½Π΅Π½Ρ Π² ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΠΉ ΠΏΠ»Π΅ΠΊΡ. ΠΠ»Ρ Π΄Π²ΡΡ
ΡΠΎΠ·Π΄Π°Π½Π½ΡΡ
ΠΏΠ»Π΅ΠΊΡΠΎΠ² ΠΎΠΏΡΠΈΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΡΠ΅ ΡΠΎΡΡΠ°Π² Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΌΠ΅ΡΠΈ ΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΠ¦Π ΡΠ΅Π°ΠΊΡΠΈΠΈ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ ΠΏΠ°Π½Π΅Π»ΠΈ Β«Π±ΠΈΠ½ΠΎΠ²Β» Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ². ΠΠΏΡΠΎΠ±Π°ΡΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ»Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π΄Π΅Π²ΡΡΠΈ Π»ΠΎΠΊΡΡΠ°Ρ
Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΈ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡΡΡ
Π‘ΠΈΠ½ΡΠ΅Π· 3-ΠΈΠ·ΠΎΠ±ΡΡΠΈΠ»Π³Π΅ΠΊΡΠ°Π³ΠΈΠ΄ΡΠΎΠΏΠΈΡΡΠΎΠ»ΠΎ[1,2-Π°]ΠΏΠΈΡΠ°Π·ΠΈΠ½-1,4-Π΄ΠΈΠΎΠ½Π°
3-Isobutylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione, [cyclo(prolyl-leucyl)], which has a wide range of biological effects, was obtained by thermolysis both the L-prolyl-L-leucine methyl ester and the methyl ester L-leucyl-L-proline, for the synthesis of which the removal of tert-butyloxycarbonyl amino protecting groups in tert-butyloxycarbonylprolyl-leucine methyl ester and tert-butyloxycarbonylleucyl-proline methyl ester under the action of a methanolic solution of hydrogen chloride and the treatment of the resulting of methyl esters hydrochlorides L-prolyl-L-leucine and L-leucyl-L-proline with an equimolar amount of triethylamine were used. The starting tert-butyloxycarbonylleucyl-proline methyl ester was prepared like the previously synthesized tert-butyloxycarbonylprolyl-leucine methyl ester by the carbodiimide method. It was found that the cyclization of the methyl ester of L-leucyl-L-proline into the desired diketopiperazine proceeds at a lower temperature than the cyclization of the methyl ester of L-prolyl-L-leucine.3-ΠΠ·ΠΎΠ±ΡΡΠΈΠ»Π³Π΅ΠΊΡΠ°Π³ΠΈΠ΄ΡΠΎΠΏΠΈΡΡΠΎΠ»ΠΎ[1,2-a]ΠΏΠΈΡΠ°Π·ΠΈΠ½-1,4-Π΄ΠΈΠΎΠ½, [ΡΠΈΠΊΠ»ΠΎ(ΠΏΡΠΎΠ»ΠΈΠ»-Π»Π΅ΠΉΡΠΈΠ»)], ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠΉ ΡΠΈΡΠΎΠΊΠΈΠΌ ΡΠΏΠ΅ΠΊΡΡΠΎΠΌ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΠΏΠΎΠ»ΡΡΠ΅Π½ ΡΠ΅ΡΠΌΠΎΠ»ΠΈΠ·ΠΎΠΌ ΠΊΠ°ΠΊ ΠΌΠ΅ΡΠΈΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΈΡΠ° L-ΠΏΡΠΎΠ»ΠΈΠ»-L-Π»Π΅ΠΉΡΠΈΠ½Π°, ΡΠ°ΠΊ ΠΈ ΠΌΠ΅ΡΠΈΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΈΡΠ° L-Π»Π΅ΠΉΡΠΈΠ»-L-ΠΏΡΠΎΠ»ΠΈΠ½Π°, Π΄Π»Ρ ΡΠΈΠ½ΡΠ΅Π·Π° ΠΊΠΎΡΠΎΡΡΡ
Π±ΡΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΡΠ½ΡΡ
Π°ΠΌΠΈΠ½ΠΎΠ·Π°ΡΠΈΡΠ½ΡΡ
Π³ΡΡΠΏΠΏ Π² ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΠΏΡΠΎΠ»ΠΈΠ»ΠΌΠ΅ΡΠΎΠΊΡΠΈΠ»Π΅ΠΉΡΠΈΠ½Π΅ ΠΈ ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»ΠΌΠ΅ΡΠΎΠΊΡΠΈΠΏΡΠΎΠ»ΠΈΠ½Π΅ ΠΏΠΎΠ΄ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠ°Π½ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° Ρ
Π»ΠΎΡΠΈΡΡΠΎΠ³ΠΎ Π²ΠΎΠ΄ΠΎΡΠΎΠ΄Π° ΠΈ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΎΠ±ΡΠ°Π·ΡΡΡΠΈΡ
ΡΡ ΠΏΡΠΈ ΡΡΠΎΠΌ Π³ΠΈΠ΄ΡΠΎΡ
Π»ΠΎΡΠΈΠ΄ΠΎΠ² ΠΌΠ΅ΡΠΈΠ»ΠΎΠ²ΡΡ
ΡΡΠΈΡΠΎΠ² L-ΠΏΡΠΎΠ»ΠΈΠ»-L-Π»Π΅ΠΉΡΠΈΠ½Π° ΠΈ L-Π»Π΅ΠΉΡΠΈΠ»-L-ΠΏΡΠΎΠ»ΠΈΠ½Π° ΡΠΊΠ²ΠΈΠΌΠΎΠ»ΡΡΠ½ΡΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎΠΌ ΡΡΠΈΡΡΠΈΠ»Π°ΠΌΠΈΠ½Π°. ΠΡΡ
ΠΎΠ΄Π½ΡΠΉ ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»ΠΌΠ΅ΡΠΎΠΊΡΠΈΠΏΡΠΎΠ»ΠΈΠ½ Π±ΡΠ» ΠΏΠΎΠ»ΡΡΠ΅Π½, ΠΊΠ°ΠΊ ΠΈ ΡΠΈΠ½ΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΡΠ°Π½Π΅Π΅ ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΠΏΡΠΎΠ»ΠΈΠ»ΠΌΠ΅ΡΠΎΠΊΡΠΈΠ»Π΅ΠΉΡΠΈΠ½, ΠΊΠ°ΡΠ±ΠΎΠ΄ΠΈΠΈΠΌΠΈΠ΄Π½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΌΠ΅ΡΠΈΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΈΡΠ° L-Π»Π΅ΠΉΡΠΈΠ»-L-ΠΏΡΠΎΠ»ΠΈΠ½Π° Π² ΡΠ΅Π»Π΅Π²ΠΎΠΉ Π΄ΠΈΠΊΠ΅ΡΠΎΠΏΠΈΠΏΠ΅ΡΠ°Π·ΠΈΠ½ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π΅Ρ ΠΏΡΠΈ Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠ΅, ΡΠ΅ΠΌ ΡΠΈΠΊΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΌΠ΅ΡΠΈΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΈΡΠ° L-ΠΏΡΠΎΠ»ΠΈΠ»-L-Π»Π΅ΠΉΡΠΈΠ½Π°
Π‘ΠΈΠ½ΡΠ΅Π· Π°ΡΠΈΠ»ΡΠ½ΡΡ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ ΠΏΡΠΎΠ»ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»Π³Π»ΠΈΡΠΈΠ½Π°ΠΌΠΈΠ΄Π°
Tert-butyloxycarbonylprolylleucylglycinamide is obtained both by the interaction of tert-butyloxycarbonylprol ylleucylglycine ethyl ester with a methanolic ammonia solution and by the reaction of glycine amide with a mixed anhydride which was synthesized from tert-butyloxycarbonylprolylleucine and isobutylchloroformate. The removal of the tert-butyloxycarbonyl group by the action of formic acid or a dioxane solution of hydrogen chloride and treatment of the resulting salts with the corresponding base yielded a prolylleucylglycinamide, by the interaction of which with acetic, benzoic or 5-phenylisoxazole-3-carboxylic acids chlorides acyl derivatives of prolylleucylglycinamide are obtained.Π’ΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΠΏΡΠΎΠ»ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»Π³Π»ΠΈΡΠΈΠ½Π°ΠΌΠΈΠ΄ ΠΏΠΎΠ»ΡΡΠ΅Π½ ΠΊΠ°ΠΊ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΡΡΠΈΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠΈΡΠ°Β ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΠΏΡΠΎΠ»ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»Π³Π»ΠΈΡΠΈΠ½Π° Ρ ΠΌΠ΅ΡΠ°Π½ΠΎΠ»ΡΠ½ΡΠΌ ΡΠ°ΡΡΠ²ΠΎΡΠΎΠΌ Π°ΠΌΠΌΠΈΠ°ΠΊΠ°, ΡΠ°ΠΊ ΠΈ ΡΠ΅Π°ΠΊΡΠΈΠ΅ΠΉ Π°ΠΌΠΈΠ΄Π° Π³Π»ΠΈΡΠΈΠ½Π° ΡΠΎ ΡΠΌΠ΅ΡΠ°Π½Π½ΡΠΌ Π°Π½Π³ΠΈΠ΄ΡΠΈΠ΄ΠΎΠΌ, ΡΠΈΠ½ΡΠ΅Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΠΈΠ·Β ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΠΏΡΠΎΠ»ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ½Π° ΠΈΒ ΠΈΠ·ΠΎ-Π±ΡΡΠΈΠ»Ρ
Π»ΠΎΡΡΠΎΡΠΌΠΈΠ°ΡΠ°. Π£Π΄Π°Π»Π΅Π½ΠΈΠ΅Β ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠΊΡΠΈΠΊΠ°ΡΠ±ΠΎΠ½ΠΈΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎΠ΄ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΌΡΡΠ°Π²ΡΠΈΠ½ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ ΠΈΠ»ΠΈ Π΄ΠΈΠΎΠΊΡΠ°Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° Ρ
Π»ΠΎΡΠΈΡΡΠΎΠ³ΠΎ Π²ΠΎΠ΄ΠΎΡΠΎΠ΄Π° ΠΈ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΎΠ±ΡΠ°Π·ΡΡΡΠΈΡ
ΡΡ ΠΏΡΠΈ ΡΡΠΎΠΌ ΡΠΎΠ»Π΅ΠΉ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΠΌ ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π°Π²Π°Π»ΠΈ ΠΏΡΠΎΠ»ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»Π³Π»ΠΈΡΠΈΠ½Π°ΠΌΠΈΠ΄, Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Ρ Ρ
Π»ΠΎΡΠ°Π½Π³ΠΈΠ΄ΡΠΈΠ΄Π°ΠΌΠΈ ΡΠΊΡΡΡΠ½ΠΎΠΉ, Π±Π΅Π½Π·ΠΎΠΉΠ½ΠΎΠΉ ΠΈΠ»ΠΈ 5-ΡΠ΅Π½ΠΈΠ»ΠΈΠ·ΠΎΠΊΡΠ°Π·ΠΎΠ»-3-ΠΊΠ°ΡΠ±ΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π°ΡΠΈΠ»ΡΠ½ΡΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΠ΅ ΠΏΡΠΎΠ»ΠΈΠ»Π»Π΅ΠΉΡΠΈΠ»Π³Π»ΠΈΡΠΈΠ½Π°ΠΌΠΈΠ΄Π°
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ 11 Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΡ
A system has been developed to identify 11 genetic markers associated with the risk of obesity: rs10852521, rs11075990, rs1121980, rs1421085, rs1477196, rs17817449, rs3751812, rs7206790, rs8047395, rs9940128 (FTO gene) and rs1137101 (LEPR gene) by minisequencing (SNaPshot analysis). The conditions for carrying out the amplification and minisequencing reactions, as well as the compositions of the reaction mixtures, were optimized so that the analysis was carried out for all 11 markers simultaneously. The resulting system was tested and showed a high degree of reproducibility and sensitivity required for the detection of these polymorphisms.Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΌΠΈΠ½ΠΈΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (SNaPshot Π°Π½Π°Π»ΠΈΠ·) ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ° Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ 11 Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΡ: rs10852521, rs11075990, rs1121980, rs1421085, rs1477196, rs17817449, rs3751812, rs7206790, rs8047395, rs9940128 (Π³Π΅Π½ FTO) ΠΈ rs1137101 (Π³Π΅Π½ LEPR). Π£ΡΠ»ΠΎΠ²ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ΅Π°ΠΊΡΠΈΠΉ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΈ ΠΌΠΈΠ½ΠΈΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΎΡΡΠ°Π²Ρ ΡΠ΅Π°ΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΡΠΌΠ΅ΡΠ΅ΠΉ ΠΎΠΏΡΠΈΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ°ΠΊ, ΡΡΠΎΠ±Ρ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎ Π²ΡΠ΅ΠΌ 11 ΠΌΠ°ΡΠΊΠ΅ΡΠ°ΠΌ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ. ΠΠΎΠ»ΡΡΠ΅Π½Π½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° Π°ΠΏΡΠΎΠ±ΠΈΡΠΎΠ²Π°Π½Π° ΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π»Π° Π²ΡΡΠΎΠΊΡΡ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠΉ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π΄Π°Π½Π½ΡΡ
ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ²
Athlome Project Consortium: a concerted effort to discover genomic and other "omic" markers of athletic performance.
Despite numerous attempts to discover genetic variants associated with elite athletic performance, injury predisposition, and elite/world-class athletic status, there has been limited progress to date. Past reliance on candidate gene studies predominantly focusing on genotyping a limited number of single nucleotide polymorphisms or the insertion/deletion variants in small, often heterogeneous cohorts (i.e., made up of athletes of quite different sport specialties) have not generated the kind of results that could offer solid opportunities to bridge the gap between basic research in exercise sciences and deliverables in biomedicine. A retrospective view of genetic association studies with complex disease traits indicates that transition to hypothesis-free genome-wide approaches will be more fruitful. In studies of complex disease, it is well recognized that the magnitude of genetic association is often smaller than initially anticipated, and, as such, large sample sizes are required to identify the gene effects robustly. A symposium was held in Athens and on the Greek island of Santorini from 14-17 May 2015 to review the main findings in exercise genetics and genomics and to explore promising trends and possibilities. The symposium also offered a forum for the development of a position stand (the Santorini Declaration). Among the participants, many were involved in ongoing collaborative studies (e.g., ELITE, GAMES, Gene SMART, GENESIS, and POWERGENE). A consensus emerged among participants that it would be advantageous to bring together all current studies and those recently launched into one new large collaborative initiative, which was subsequently named the Athlome Project Consortium